Business Wire

NY-REMOTE

13.7.2021 14:02:07 CEST | Business Wire | Press release

Share
Remote Raises $150 Million Series B Led By Accel to Power a New, Global Workforce

Remote , a leading HR tech platform and provider of global employer of record services and international contractor management, today announced it has raised a $150 million Series B round led by Accel with participation from existing investors including Sequoia, Index Ventures, Two Sigma, General Catalyst and Day One Ventures, and is now valued at over $1 billion. The new round comes in the midst of a massive transformation of the workforce that has ushered in a new era of remote work and empowered companies to recruit talent from anywhere in the world.

The shift to distributed employment created unprecedented demand for Remote’s services: since their $35 million Series A in November 2020, Remote grew its customer base by 7x and increased its users by more than 10x. Remote’s revenue has grown by 65x over the past year, and employee headcount has gone from 50 to 220 employees working remotely in 45 countries since November 2020. Remote is the only Employer of Record (EOR) that owns 100% of its global infrastructure, has legal entities in more than 50 countries with plans to have fully operational legal entities in more than 80 countries by the end of 2021, and in the rest of the world by the end of 2022.

In conjunction with the funding, Remote is announcing the launch of a first-to-market Global Employee API, that enables HR and payroll companies to leverage Remote’s vertically-integrated global employment capabilities and infrastructure within their own platforms. Remote’s Global Employee API is being used by top Employee Management Platform Rippling to allow customers to compliantly onboard international employees, consolidate domestic and international payroll, and accelerate their global expansion.

"Through our partnership with Remote, Rippling’s clients can hire, onboard, and pay someone anywhere in the world — all through one HR system, with one set of reports and analytics, and with one place to make employee changes, across the globe,” shared Parker Conrad, CEO of Rippling. “We chose to partner with Remote because of their global infrastructure, in-house expertise managing entities all over the world, and their strategy to closely integrate their service with clients' other business systems. Rippling + Remote will give HR leaders assurance that their global teams always meet local tax and labor laws, no matter where they work."

With the new funding, Remote will expand their advisory services to include guidance on global benefits, equity incentive planning, visa and immigration support, employee relocation, and more. Remote plans to build its own financial services infrastructure that will streamline and add transparency and speed to international payroll processes, which at present are reliant on external parties. An evolution of Remote’s vertically integrated infrastructure strategy, their financial services will include instant payouts and stock options payment plans all within the Remote platform.

"Our goal is to remove the barriers to hiring internationally, empower our customers to scale, and provide access to job opportunities all over the world,” said Job van der Voort, CEO of Remote. “Our seasoned team has spent the past year expanding our global infrastructure, to deliver elegant solutions to complex international legal challenges, and with this funding, we will be adding new products, services and partnerships."

“Remote is at the center of a profound shift in the way that companies hire. Their new Global Employee API opens up access to Remote’s robust global employment infrastructure and knowledge map, and will help any HR provider expand internationally at a speed impossible before. Remote’s future vision as a financial services provider will consolidate complicated processes into one trusted platform, and we’re excited to partner with the global leader in the quickly emerging category of remote work,” said Miles Clements, Partner at Accel.

In addition to the upcoming Global Employee API launch, Remote has partnered with Greenhouse, the leading applicant tracking system and recruiting software, to integrate with their robust employee information data and increase the speed and accuracy of Remote customers’ onboarding process.

Hiring internationally has traditionally been a costly and cumbersome process that was largely accessible only to multinational corporations with large HR teams. With Remote, companies can now employ talent around the world through a platform of global payroll, tax, benefits, legal and compliance services. Free for international contractors, with pricing starting at $149 per month for early stage startups, Remote provides an unparalleled level of expertise, IP protection, and cost efficiency to customers and their global workforce.

About Remote

Remote is the leading self-serve global employment platform with the only network of 100% owned legal entities around the world. Remote has synthesized international legal systems into a seamless experience for its customers, enabling them to compliantly employ anyone, anywhere. Remote's Global Employee API makes it possible for HR tech partners to leverage our legal infrastructure for global payroll, benefits and compliance. Founded in 2019 by Job van der Voort (former VP of Product at GitLab) and Marcelo Lebre (former VP of Engineering at Unbabel), Remote is a fully distributed company with employees based all over the world.

For more information, visit www.remote.com .

About Accel

Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Braintree, Cloudera, Crowdstrike, DJI, DocuSign, Dropbox, Etsy, Facebook, Flipkart, Freshworks, Jet, Pillpack, Qualtrics, Slack, Spotify, Supercell, Tenable, UiPath, and Venmo are among the companies Accel has backed over the past 35+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com or www.twitter.com/accel .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye